NASDAQ:WVE

WAVE Life Sciences (WVE) Stock Price, News & Analysis

WAVE Life Sciences logo
$2.56 -0.16 (-5.88%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.66 +0.09 (+3.71%)
As of 11/20/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About WAVE Life Sciences Stock (NASDAQ:WVE)

Advanced

Key Stats

Today's Range
$2.55
▼
$2.79
50-Day Range
$2.56
▼
$4.58
52-Week Range
$2.55
▼
$21.73
Volume
2.28 million shs
Average Volume
2.94 million shs
Market Capitalization
$504.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.44
Consensus Rating
Moderate Buy

Company Overview

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression.

Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

WAVE’s work is focused on research and clinical development rather than a portfolio of marketed medicines. Its programs are designed to address serious diseases with limited treatment options, and the company evaluates its candidates through laboratory and clinical studies.

AI Generated. May Contain Errors.

WAVE Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

WVE MarketRank™: 
2.560291643295 of 5 stars

WAVE Life Sciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 463rd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    WAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 15 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    WAVE Life Sciences has a consensus price target of $20.44, representing about 698.6% upside from its current price of $2.56.

  • Amount of Analyst Coverage

    WAVE Life Sciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about WAVE Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for WAVE Life Sciences are expected to decrease in the coming year, from ($1.08) to ($1.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of WAVE Life Sciences is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of WAVE Life Sciences is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    WAVE Life Sciences has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.84% of the float of WAVE Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    WAVE Life Sciences has a short interest ratio ("days to cover") of 6.76.
  • Change versus previous month

    Short interest in WAVE Life Sciences has recently decreased by 2.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    WAVE Life Sciences does not currently pay a dividend.

  • Dividend Growth

    WAVE Life Sciences does not have a long track record of dividend growth.

  • News Sentiment

    WAVE Life Sciences has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.
  • Search Interest

    Only 5 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, WAVE Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.34% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about WAVE Life Sciences' insider trading history.
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WVE Stock News Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Wave: 3 Key Takeaways for Long-Term Investors
See More Headlines

WVE Stock Analysis - Frequently Asked Questions

WAVE Life Sciences' stock was trading at $17.00 on January 1st, 2026. Since then, WVE stock has decreased by 84.9% and is now trading at $2.56.

WAVE Life Sciences Ltd. (NASDAQ:WVE) released its earnings results on Wednesday, October, 28th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The firm had revenue of $13.16 million for the quarter, compared to analysts' expectations of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative trailing twelve-month return on equity of 44.66%.
Read the conference call transcript
.

WAVE Life Sciences (WVE) raised $102 million in an initial public offering (IPO) on Wednesday, November 11th 2015. The company issued 6,375,000 shares at $15.00-$17.00 per share.

WAVE Life Sciences' top institutional investors include State Street Corp (2.87%), Readystate Asset Management LP (2.81%), Marshall Wace LLP (1.86%) and Algert Global LLC (1.03%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Chandra Vargeese, Paul Bolno, Gregory L Verdine, Kyle Moran, Chris Francis, Heidi L Wagner, Mark Corrigan, Ken Takanashi, Christian O Henry and Adrian Rawcliffe.
View institutional ownership trends
.

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Oracle (ORCL), Advanced Micro Devices (AMD), Broadcom (AVGO) and Applied Materials (AMAT).

Company Calendar

Last Earnings
10/28/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:WVE
CIK
1631574
Employees
317
Year Founded
2012

Price Target and Rating

High Price Target
$43.00
Low Price Target
$10.00
Potential Upside/Downside
+698.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$204.38 million
Net Margins
-296.86%
Pretax Margin
-296.86%
Return on Equity
-44.66%
Return on Assets
-36.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.38
Quick Ratio
8.38

Sales & Book Value

Annual Sales
$42.73 million
Price / Sales
11.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.04 per share
Price / Book
1.25

Miscellaneous

Outstanding Shares
197,230,000
Free Float
149,223,000
Market Cap
$504.91 million
Optionable
Optionable
Beta
-1.40

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:WVE) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners